Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level

Journal of the American College of Cardiology

Volumn 47, Issue 2, 2006, Pages 338-341

  Bleske, Barry E ^a   Nicklas, John M ^b   Bard, Robert L ^b   Brook, Robert D ^b   Gurbel, Paul A ^c   Bliden, Kevin P ^c   Rajagopalan, Sanjay ^d   Pitt, Bertram ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIBODY; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOOP DIURETIC AGENT; LOW DENSITY LIPOPROTEIN; NITRATE; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PADGEM PROTEIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM; FEMALE; HEART FAILURE; HEART RATE VARIABILITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MYOCARDITIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VAGUS TONE;

C-REACTIVE PROTEIN; CARDIOMYOPATHY, DILATED; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; P-SELECTIN; PEPTIDE FRAGMENTS; RECEPTORS, TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE-1; VENTRICULAR REMODELING;

EID: 30344455355     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.06.087     Document Type: Article

References (17)

1. T.B. Horwich, R. MacLellan, G.C. Fonarow Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure J Am Coll Cardiol 43 2004 642 648
2. D. Mozaffarian, R. Nye, W.C. Levy Statin therapy is associated with lower mortality among patients with severe heart failure Am J Cardiol 93 2004 1124 1129
3. J. Kjekshus, T.R. Pedersen, A.G. Olsson, O. Faergeman, K. Pyorala The effects of simvastatin on the incident of heart failure in patients with coronary heart disease J Card Fail 3 1997 249 254
4. A. Hognestad, K. Dickstein, E. Myhre, S. Snapinn, J. Kjekshus Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure Am J Cardiol 93 2004 603 606
5. D. Tousoulis, C. Antoniades, E. Bosinakou Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure Heart 91 2005 27 31
6. K. Node, M. Fujita, M. Kitakaze, M. Hori, J.K. Kiao Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 108 2003 839 843
7. U. Laufs, S. Wassmann, S. Schackmann, C. Heeschen, M. Bohm, G. Nickenig Beneficial effects of statins in patients with non-ischemic heart failure Z Kardiol 93 2004 103 108
8. M. Rauchhaus, A.L. Clark, W. Doehner The relationship between cholesterol and survival in patients with chronic heart failure J Am Coll Cardiol 42 2003 1933 1940
9. T.B. Horwich, M.A. Hamilton, W.R. Maclellan Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure J Card Fail 8 2002 216 224
10. M. Rauchhaus, A.J. Coats, S.D. Anker The endotoxin-lipoprotein hypothesis Lancet 356 2000 930 933
11. R.D. Brook, R.L. Bard, L. Glazewski, C. Kehrer, P.F. Bodary, D.T. Eitzman, S. Rajagopalan Short-term weight loss improves the metabolic syndrome but not conduit vascular endothelial function in overweight adults Am J Cardiol 93 2004 1012 1016
12. E. Ascer, M.C. Bertolami, M.L. Venturinelli Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients Atherosclerosis 177 2004 161 166
13. H. Oral, S.G. Fisher, W.P. Fay, S.N. Singh, R.D. Fletcher, F. Morady Effects of amiodarone on tumor necrosis factor-α levels in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol 83 1999 388 391
14. D. Tousoulis, H. Homaei, N. Ahmed, G. Asimakopoulos, E. Zouridakis, P. Toutouzas, G.J. Davies Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy Am Heart J 141 2001 277 280
15. B.E. Bleske, R.A. Willis, M. Anthony The effect of pravastatin and atorvastatin on coenzyme Q10 Am Heart J 142 2001 e2
16. R. Laaksonen, K. Jokelainen, T. Sahi, M.J. Tikkanen, J.J. Himberg Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans Clin Pharmacol Ther 57 1995 62 66
17. B.E. Bleske The "PROMISE" of a good hypothesis statins and CoQ10 therapy Curr Top Nutriceutical Res 3 2005 159 162